Abstract:Abstract Case A 66-year-old man with history of anxiety, depression, and complex regional pain syndrome presented to a psychiatric hospital with suicidal ideation. Admission laboratory studies demonstrated hypercalcemia (Ca 14.2 mg/dL) with kidney injury (Cr 3.26). He endorsed taking 5 to 16 (average 8-9) tablets of 1000 IU Vitamin D daily for 10 years. He had heard about the health benefits of Vitamin D and believed it gave him a euphoric effect. Work-up demonstrated elevated ionized calcium (1.63 mmol/L), normal serum phosphorus (3.8 mg/dL), low total protein (6.24 g/dL), normal total albumin (3.42 g/dL), and negative serum protein electrophoresis. Intravenous hydration with normal saline at 200 cc/hr was initiated along with intravenous furosemide. Additional work up demonstrated a suppressed parathyroid hormone level (10pg/ml). 25-hydroxyvitamin D3 (25-(OH)D3) levels were elevated beyond the measurable range (> 155.9 pg/mL). The plasma 1α,25-dihydroxyvitamin D3 (1α,25 (OH)2D3) was normal at 44 pg/mL (range 18-64 pg/mL). With intravenous fluid administration, the patient's ionized calcium level decreased and his creatinine improved. However, 48 hours after the fluids were discontinued on hospital day 3, the ionized calcium and serum creatinine rose once again. Due to the long half-life of Vitamin D and the up-trending calcium levels, he received 60mg of intravenous Pamidronate on hospital day 8. On discharge on hospital day 11, his renal function was stable (Cr 2.24) with normal ionized calcium (1.27 mmol/L). His psychiatric symptoms had resolved. Discussion The two most common causes of hypercalcemia are primary hyperparathyroidism and malignancy. Less commonly, vitamin D-mediated hypercalcemia may result from ectopic 1,25-dihydroxyvitamin D production or excessive Vitamin D ingestion. The known upper limit of daily Vitamin D intake in an adult that will cause no adverse risk is 4000 IU per day. Vitamin D is a fat-soluble vitamin with a half-life of approximately 2 months. The liver converts Vitamin D3 to the metabolite 25-(OH)D3, which has a half-life of 15 days, and the kidney further metabolizes this to 1α,25 (OH)2D3, which has a half-life of 15 hours. Therefore, this patient's 25-(OH)D3 was expected to remain at toxic levels for an unknown time period, placing him at risk of prolonged hypercalcemia with further deterioration of his renal function. There is no standard of care established for patients with vitamin D toxicity. Pamidronate, normally contraindicated for GFR <30 mL/min, was administered after nephrology consultation. Information about vitamin D toxicity is primarily gleaned from case reports and series. This case report serves as a model for study of Vitamin D toxicity in humans for understanding the long-term management in patients with chronic vitamin D toxicosis presenting with renal failure. Presentation: No date and time listed

Recalcitrant hypercalcemia in a dialysis patient: Case report, literature review, and proposed management algorithm

A case of advanced chronic kidney disease with severe hypocalcemia, how to safely manage and dialyze?

Regression of Calcinosis Following Treatment with Radiofrequency Thermoablation for Severe Secondary Hyperparathyroidism in a Hemodialysis Patient

Denosumab Treatment for Refractory Hypercalcemia in a Hemodialysis Patient with Tertiary Hyperparathyroidism

Sustained hypophosphatemia after denosumab in a patient on hemodialysis

Hyperphosphataemia in renal failure: causes, consequences and current management

Too Much of a Good Thing: Severe Hypercalcemia Presenting with Lethargy and Kidney Failure

Recurrent Disturbance of Consciousness in a Peritoneal Dialysis Patient with Severe Hypercalcemia Caused by Daily Low-Dose Keto Acids Supplementation

Vitamin D Toxicity Managed with Peritoneal Dialysis

A Case of Recurrent Severe Hypocalcemia with Prolonged Hospitalization and Readmissions After Single Dose of Denosumab in Metastatic Prostate Cancer Patient

Mineral and Bone Disorder in Chinese Dialysis Patients: a Multicenter Study

Catastrophic Femoral Vein Thrombosis in a Patient with Hypercalcemia Due to Parathyroid Adenoma: a Case Report

Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta‐analysis of randomized studies

A Curious Case of Severe Recurrent Hypocalcemia

The present status and the related factors of abnormal calcium- phosphorous metabolism in mainte-nance hemodialysis patients

A study of combination therapy for hyperphosphatemia with calcium-containing phosphate binders and low-calcium dialysate in hemodialysis patients.

LBODP020 Treatment Of Hypercalcemia Due To Prolonged, Excessive Vitamin D Intake

Calciphylaxis: a devastating complication of derangements of calcium-phosphorus metabolism--a case report and review of the literature

A Challenging Case of Vitamin D Toxicity Responding to Cinacalcet

Treatment of a patient with inoperable tumoral calcinosis associated with end stage kidney disease: A case report

Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients